Home › Mieloma multiplo › North Carolina › Durham
Studi clinici su Mieloma multiplo a Durham, NC
37 studi su Mieloma multiplo cercano partecipanti presso sedi a Durham e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
In reclutamentoFase 3
- Research Site, Chapel Hill · a 10 mi di distanza
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
In reclutamentoFase 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · a 10 mi di distanza
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
In reclutamentoFase 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
In reclutamentoFase 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · a 10 mi di distanza
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
In reclutamentoFase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
In reclutamentoFase 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 2
- University of North Carolina Medical Center, Chapel Hill · a 10 mi di distanza
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
In reclutamentoFase 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · a 10 mi di distanza
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
In reclutamentoFase 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · a 13 mi di distanza
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
In reclutamentoFase 1/2
- GSK Investigational Site, Chapel Hill · a 10 mi di distanza
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
In reclutamentoFase 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
In reclutamentoFase 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
In reclutamentoFase 3
- Research Site, Durham
- Research Site, Chapel Hill · a 10 mi di distanza
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
In reclutamento
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · a 10 mi di distanza
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
In reclutamentoFase 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
In reclutamentoFase 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · a 10 mi di distanza
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
In reclutamentoFase 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · a 10 mi di distanza
Selinexor and Backbone Treatments of Multiple Myeloma Patients
In reclutamentoFase 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 1
- University of North Carolina /ID# 251203, Chapel Hill · a 10 mi di distanza
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
In reclutamentoFase 1
- University of North Carolina at Chapel Hill, Chapel Hill · a 10 mi di distanza
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
In reclutamentoFase 2
- University of North Carolina (Data Collection Only), Chapel Hill · a 10 mi di distanza
Registry of Older Patients With Cancer
In reclutamentoStudio osservazionale
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · a 10 mi di distanza
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
In reclutamentoFase 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
In reclutamentoFase 2
- University of North Carolina, Chapel Hill · a 10 mi di distanza
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
In reclutamentoFase 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi di distanza
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
In reclutamentoFase 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · a 10 mi di distanza
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
In reclutamentoFase 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · a 13 mi di distanza
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
In reclutamentoFase 1
- University of North Carolina, Chapel Hill · a 10 mi di distanza
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
In reclutamentoFase 1
- University of North Carolina, Chapel Hill · a 10 mi di distanza
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
In reclutamentoFase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · a 10 mi di distanza
Registry for Adults With Plasma Cell Disorders (PCD's)
In reclutamentoStudio osservazionale
- North Carolina Cancer Hospital, Chapel Hill · a 10 mi di distanza
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
In reclutamentoStudio osservazionale
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · a 10 mi di distanza
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
In reclutamentoFase 1
- Duke University Health System (DUHS), Durham
Studi su Mieloma multiplo in altre città
- New York City, NY60 studi
- Boston, MA42 studi
- Atlanta, GA41 studi
- Houston, TX38 studi
- Nashville, TN32 studi
- Denver, CO27 studi
- Rochester, MN24 studi
- St. Louis, MO24 studi
- Columbus, OH24 studi
- Baldwin Park, CA23 studi
- Chicago, IL22 studi
- Seattle, WA22 studi
Altri studi a Durham
- Cancro al seno63 studi
- Cancro (tutti i tipi)58 studi
- Cancro del polmone non a piccole cellule39 studi
- Cancro metastatico33 studi
- Leucemia mieloide acuta33 studi
- Cancro ai polmoni32 studi
- Cancro alla prostata32 studi
- Cancro colorettale28 studi
- Leucemia linfatica cronica27 studi
- Cancro ovarico27 studi
- Insufficienza cardiaca26 studi
- Cancro pancreatico24 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.